These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 2190321)

  • 21. Results of long-term iron-chelating therapy.
    Gabutti V; Piga A
    Acta Haematol; 1996; 95(1):26-36. PubMed ID: 8604584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 26. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
    Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
    Greenberg PL
    J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New advances in iron chelation therapy.
    Cohen AR
    Hematology Am Soc Hematol Educ Program; 2006; ():42-7. PubMed ID: 17124038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron chelation.
    Chandy M
    J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
    [No Abstract]   [Full Text] [Related]  

  • 33. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 34. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
    Chen SH; Liang DC; Lin HC; Cheng SY; Chen LJ; Liu HC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):651-3. PubMed ID: 16344669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of long term iron chelation treatment with deferoxamine.
    Davis BA; Porter JB
    Adv Exp Med Biol; 2002; 509():91-125. PubMed ID: 12572991
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood disorders: future trends in iron chelation.
    Jordan D; Kontoghiorghes G
    Nurs Stand; 1990 Oct 24-30; 5(5):25-7. PubMed ID: 2124864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.